Indolent B-cell Lymphoma
Conditions
Brief summary
This is a national multicenter, randomized controlled, open, dose-optimized Phase IV study. It is expected to enroll approximately 88 patients with relapsed/refractory indolent B-cell lymphoma. The aim is to evaluate the efficacy and safety of linperlisib in the treatment of patients with relapsed/refractory indolent B-cell lymphoma at two doses/modes of administration (clinically recommended dose/mode and optimized dose/mode).
Detailed description
This is a national multicenter, randomized controlled, open, dose-optimized Phase IV study. It is expected to enroll approximately 88 patients with relapsed/refractory indolent B-cell lymphoma. The aim is to evaluate the efficacy and safety of linperlisib in the treatment of patients with relapsed/refractory indolent B-cell lymphoma at two doses/modes of administration (clinically recommended dose/mode and optimized dose/mode). Patients were divided to two groups by stratified randomization according to tumor type (FL, CLL/SLL, MZL, others) during the screening period. Both groups were orally administered with a starting dose of 80mg qd for 21 days. On the 21st day of the 4th cycle, if the patient's tumor does not progress and there is no intolerable toxicity, after the researchers determined that medication could be continued, one group of patients continued to take 80mg qd dose continuously, and the other group of patients continued to take 80mg qd dose continuously for two weeks per cycle and stopped for one week, and safety and tumor efficacy evaluation were conducted regularly. The maximum duration of treatment is two years until the disease progresses, toxicity becomes intolerable, or the investigator determines that it is not appropriate to continue treatment.
Interventions
DRUGLinperlisib
Linperlisib is a small molecule inhibitor of phosphoinositol 3-kinase-δ (PI3K-δ)
Sponsors
Shanghai YingLi Pharmaceutical Co. Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with r/r indolent B-cell lymphoma confirmed by histology or cytology, mainly follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma (MZL), and lymphoplasmacytic lymphoma/macroglobulinemia (LPL/WM), 2. ECOG performance status (PS) 0 \ 2 points, 3. Expected survival ≥3 months, 5\) At least one measurable lesion was present in patients other than CLL, LPL/WM; 6) Good organ function level, 7) The elution period from the end of previous anti-tumor therapy (including radiotherapy, chemotherapy, immunotherapy, surgery or molecular targeted therapy) to participation in this trial is ≥4 weeks, in which the elution period of small-molecule targeted drugs and Chinese medicines with anti-tumor effects is ≥14 days.
Exclusion criteria
1. Those who have progressed with antitumor drugs targeting PI3Kδ (except for those who cannot tolerate them), 2. There is a third space effusion (such as a large amount of pleural fluid and ascites) that the investigators judge to be uncontrollable, 3. Steroid hormone dosage (equivalent amount of prednisone) was greater than 20mg/ day for 4 weeks before enrollment, and continuous use was more than 14 days, 4. Inability to swallow, chronic diarrhea or intestinal obstruction, there are multiple factors that affect drug use and absorption, 5. Allergic constitution, or known allergic history of the drug components, 6. Patients with active viral, bacterial or fungal infections (such as pneumonia) within 4 weeks prior to enrollment; Or had uncontrolled pulmonary fibrosis, acute lung disease, or interstitial lung disease within 4 weeks prior to enrollment, 7. Infected with HBV and HCV, 8. History of immune deficiency, 9. Moderate or severe heart disease, 10. Have undergone major surgery within 28 days before signing informed consent, or plan to undergo major surgery during the study period, 11. The first study of patients with a history of other malignancies within 5 years prior to drug administration (except for patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, or other cancers in situ without disease recurrence within 2 years), 12. Received autologous hematopoietic stem cell transplantation within 90 days before the first medication,
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | From the first dose to the date of disease progression or date of death from any cause, whichever comes first，up to 24months | The time from the first dose of study treatment to first documented disease progression or death due to any cause, whichever occurs first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate | From the first dose to the date of disease progression or date of death from any cause, whichever comes first，up to 24months | The proportion of subjects who have a Complete Response or Partial Response |
| Overall survival | From the first dose to the date of death from any cause, whichever comes first，up to 24months | The time from the first dose of study treatment to death for any reason. |
| Adverse event | From enrollment receiving Linperlisib to 30 days after the last linperlisib treatment. | Incidence of adverse events evaluated by NCI CTCAE v5.0 and associated dose of linperlisib |
| Serious adverse event | From enrollment receiving Linperlisib to 30 days after the last linperlisib treatment. | Incidence of serious adverse event and associated dose of linperlisib |
Contacts
Primary ContactJun Ma
Backup ContactDonglu Zhao
Outcome results
None listed